Severe aplastic anemia after BTN162b2 mRNA COVID-19 vaccination in a patient undergoing hemodialysis
F Arima - [Rinsho Ketsueki] The Japanese Journal of Clinical …, 2023 - europepmc.org
F Arima
[Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 2023•europepmc.orgAlthough vaccination against coronavirus infection 2019 (COVID-19) has been found to be
effective, reports of adverse reactions continue to appear. We report the development of
severe aplastic anemia post BTN162b2 mRNA COVID-19 vaccination in patient undergoing
dialysis. The pathogenesis and risk factors for post-vaccination aplastic anemia remain
unclear. We must remain vigilant to aplastic anemia following COVID-19 vaccination. The
risk of aplastic anemia should be identified, and management methods should be …
effective, reports of adverse reactions continue to appear. We report the development of
severe aplastic anemia post BTN162b2 mRNA COVID-19 vaccination in patient undergoing
dialysis. The pathogenesis and risk factors for post-vaccination aplastic anemia remain
unclear. We must remain vigilant to aplastic anemia following COVID-19 vaccination. The
risk of aplastic anemia should be identified, and management methods should be …
Although vaccination against coronavirus infection 2019 (COVID-19) has been found to be effective, reports of adverse reactions continue to appear. We report the development of severe aplastic anemia post BTN162b2 mRNA COVID-19 vaccination in patient undergoing dialysis. The pathogenesis and risk factors for post-vaccination aplastic anemia remain unclear. We must remain vigilant to aplastic anemia following COVID-19 vaccination. The risk of aplastic anemia should be identified, and management methods should be established.
europepmc.org